ClinicalTrials.gg
CompletedNCT05283746Updated Jul 15, 2022

A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function

A Phase 1 interventional study of Epetraborole in Renal Insufficiency, sponsored by AN2 Therapeutics, Inc. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by AN2 Therapeutics, Inc · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
176th of 468
40 · median 32
Started
2022
with 25 others
Phase 1
232 of 553
14 open now
Registered
455th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 176th largest by enrollment of the 468 interventional ones that give a count, is one of 26 that started in 2022, is one of 232 in phase 1, and was the 455th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1 study to evaluate the pharmacokinetics (PK), safety and tolerability of epetraborole tablets in adult subjects with normal renal function, subjects with various degrees of renal impairment, and subjects with end-stage renal disease (ESRD) receiving intermittent hemodialysis (IHD) therapy.

Read the detailed description

This is a multicenter, open-label, non-randomized, parallel group study in which a total of 40 subjects will be enrolled in one of 5 cohorts (8 subjects per cohort). Subjects will be enrolled based on their estimated glomerular filtration rate (eGFR) calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

  • Cohort 1: Normal renal function (eGFR ≥ 90 mL/min/1.73 m2)
  • Cohort 2: Mild renal impairment (eGFR ≥ 60 and \< 90 mL/min/1.73 m2)
  • Cohort 3: Moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min/1.73 m2)
  • Cohort 4: Severe renal impairment (eGFR \< 30 mL/min/1.73 m2)
  • Cohort 5: ESRD (eGFR \< 15 mL/min/1.73 m2) receiving IHD. Subjects must be stable and receiving IHD at least 3 times a week for at least 3 months prior to Screening.
03

Conditions studied

  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects:

    1. Adult males or females of 18 years of age or older at the time of Screening
    2. Willing and able to provide written
    3. between 18.0 and 40.0 kg/m2 (inclusive) and weight of at least 50.0 kg
    4. Have suitable venous access for blood sampling
    5. Light-, non- or ex-smoker (A light smoker is defined as someone using 10.0 nicotine units or less per day for at least 90 days prior to the first study drug administration. An ex smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration)
    6. Ability and willingness to abstain from alcohol from 48 hours prior to the first study drug administration until discharge from the clinical unit
    7. Be willing and able to comply with all study assessments and adhere to the protocol schedule, including the entire confinement period and the follow-up visit
    8. If female of , must agree to and comply with using 1 barrier method (eg, female condom or male partner using a condom) with 1 other highly effective method of (eg, oral contraceptive, implant, injectable, indwelling intrauterine device, vasectomized partner), or sexual abstinence, for the duration of the study (from signing of consent to the follow-up visit) and for 30 days after last study drug administration. Females of childbearing potential must also agree not to donate ova or oocytes (ie, human eggs) during the study, and for 1 menstrual cycle after completion of the study. To be considered of non-childbearing potential, a female must have had a tubal ligation, hysterectomy, bilateral salpingo oophrectomy, or be menopaused (last menstruation >12 months prior to the first study drug administration and follicle stimulating hormone in menopausal range). Provision of written documentation is not required for female sterilization and oral confirmation is adequate.
    9. Male subjects, if sexually active with a female partner of childbearing potential, must agree to and comply with using 1 barrier method of birth control (eg, male condom) with 1 other highly effective method of birth control in their partner (eg, oral contraceptive; implant, injectable, indwelling intrauterine device), or sexual abstinence, and must not donate sperm, for the duration of the study (from signing of consent to the follow-up visit) and for 90 days after last study drug administration

      Cohort 1:

    10. Medically and hemodynamically stable without CS abnormalities at the screening visit or Day -1, based on physical examination, vital signs, 12-lead , and laboratory results
    11. Normal renal function with ≥ 90 mL/min/1.73m2, calculated using the CKD-EPI equation. A 24-hour urine collection for test may be conducted prior to Day -1 to confirm the healthy renal function status if, as judged by an Investigator, the result of the eGFR calculated using the CKD-EPI equation at Screening does not reflect the subject's true renal function.

      Cohorts 2 to 4:

    12. Renal impairment with eGFR ≥ 60 and \< 90 mL/min/1.73m2 (Cohort 2), ≥ 30 and \< 60 mL/min/1.73m2 (Cohort 3), or \< 30 mL/min/1.73m2 (Cohort 4), calculated using the CKD-EPI equation.

      Cohort 5:

    13. Subjects with ESRD (eGFR \< 15 mL/min/1.73m2) receiving IHD at least 3 times per week for at least 3 months at Screening.

      Cohorts 2 to 5:

    14. Medically and hemodynamically stable without CS acute or chronic illness other than renal impairment that may impact the assessment of PK and safety as assessed by the Investigator, based on physical examination, vital signs, 12-lead ECG, and laboratory results

Exclusion criteria

Exclusion Criteria:

All subjects:

  1. Female who is lactating or is pregnant according to the pregnancy test at Screening or prior to the first study drug administration
  2. Any CS medical history or abnormal findings upon physical examination, or clinical laboratory tests, not specifically excluded in other criteria below that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject
  3. interval duration > 500 msec obtained as an average from the triplicate ECGs taken at least 1 minute apart after at least 5 minutes in a semi-supine, quiet rest position at Screening or prior to the first study drug administration
  4. Results of biochemistry tests for (ALT), aspartate aminotransferase (AST), and greater than 1.5 × the (ULN) for the reference laboratory, or history of chronic liver disease, cirrhosis, or biliary disease. For subjects with Gilbert's Syndrome, the subject may be included in the study at the discretion of the Investigator if the bilirubin levels are within the range for this condition.
  5. Recent history (within 6 months) of known or suspected Clostridioides difficile infection
  6. History of seizure disorder except childhood history of febrile seizures
  7. Positive drug/alcohol testing at Screening or prior to the first study drug administration unless the positive drug screen is due to prescription drug use that is approved by the Investigator and the Sponsor's Medical Monitor
  8. Positive testing for , surface antigen, or virus antibody at Screening
  9. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months prior to Screening
  10. History of reaction or anaphylaxis to any medication, unless deemed not CS by an Investigator
  11. Donation of blood or plasma within 30 days prior to the first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to the first study drug administration
  12. Receipt of an drug within 30 days or 5 half-lives prior to the first administration of study drug, whichever is longer
  13. Any other condition or prior therapy, which, in the opinion of an Investigator, would make the volunteer unsuitable for this study, including unable to cooperate fully with the requirements of the study protocol or likely to be non-compliant with any study requirements

    Cohort 1:

  14. , hematocrit, white blood cell count, or count less than the lower limit of normal range of the reference laboratory, unless deemed not CS by an Investigator
  15. Current or anticipated concomitant medications, defined as the use of any over the counter (OTC) medications within 7 days prior to study drug administration or use of prescription medications, health supplements, and herbal remedies taken within 14 days prior to study drug administration Exceptions: Hormonal and intermittent, as-needed acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of transient headache or other minor ache/pain. Discussion between the Principal Investigator and the Sponsor's Medical Monitor is encouraged regarding the acceptability of any medications prior to study drug administration.

    Cohorts 2 to 5:

  16. Hemoglobin \< 10.0 g/dL, white blood cell \< 3,000 cells/L, or platelet count \< 100,000 cells/L
  17. Current or anticipated concomitant medications with the exception of hormonal contraceptives, as-needed acetaminophen or NSAIDs for the treatment of transient, minor aches/pain, or any medication deemed essential for the management of renal impairment and the treatment of concomitant stable medical conditions as per the discretion of the Investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Open Label

    All subjects in Cohorts 1-4 receive 500 mg epetraborole once; Subjects on Cohort 5 receive 500 mg epetraborole twice

    Drug: Epetraborole

Interventions

  • Epetraborole hydrochloride 250 mg tablets for oral administration

    Also known as: AN2-501971

06

What researchers measure

Primary outcomes

  1. Characterize the PK Profile of Epetraborole and M3: Maximum Plasma Concentration

    Determination of the maximum observed plasma concentration (Cmax)

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  2. Characterize the PK Profile of Epetraborole and M3: Area Under the Plasma Concentration Versus Time Curve from Time 0 to the Last Time Point Evaluated

    Determine the area under the plasma concentration versus time curve from time 0 to the last time point evaluated (AUC0-t)

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  3. Characterize the PK Profile of Epetraborole and M3: Area Under the Plasma Concentration Versus Time Curve from Time 0 to 24 hours

    Determine the area under the plasma concentration versus time curve from time 0 to 24 hours (AUC0-24)

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  4. Characterize the PK Profile of Epetraborole and M3: Area Under the Plasma Concentration Versus Time Curve from Time 0 to Infinity

    Determine area under the drug concentration versus time curve, from time zero to infinity (AUC0-∞)

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  5. Characterize the PK Profile of Epetraborole and M3: Apparent total plasma clearance of drug

    Determine the apparent total plasma clearance of drug (CL/F)

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  6. Characterize the PK Profile of Epetraborole and M3: Time to Maximum Plasma Concentration

    Determination the time to maximum plasma concentration (Tmax)

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  7. Characterize the PK Profile of Epetraborole: Plasma from Hemodialysis Flow

    Determine the AUC from 0 to the last quantifiable concentration AUClast immediately after the end of dialysis period from inflow (arterial) line

    Time frame: Cohort 5: Day 5

  8. Characterize the PK Profile of Epetraborole:Plasma from Hemodialysis Flow

    Determine the AUC from 0 to the last quantifiable concentration AUClast immediately after the end of dialysis period from inflow (venous) line

    Time frame: Cohort 5: Day 5

  9. Characterize the PK Profile of Epetraborole and M3 in Urine: Cumulative drug excreted in urine over time

    Determine the cumulative amount excreted over all time intervals (0 to T), calculated as the sum of all amounts excreted from each interval (t1-t2)

    Time frame: Cohorts 1-4: Day 1 to Day 4

  10. Characterize the PK Profile of Epetraborole and M3 in Urine: Unchanged drug excreted in urine during the time interval

    Determine the fraction of unchanged drug excreted in urine during the time interval (expressed in %, calculated) for parent drug only

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  11. Characterize the PK Profile of Epetraborole and M3 in Urine: Renal Clearance

    Determine renal clearance (Ae(0-t)/ AUC0-T) for parent drug only

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  12. Characterize the PK Profile of Epetraborole and M3 in Dialysate: Concentration in full dialysate

    Determine amount of drug measured in the whole dialysate volume during dialysis period

    Time frame: Cohort 5: Day 5

  13. Characterize the PK Profile of Epetraborole and M3 in Urine: Dialysis clearance

    Determine the Dialysis clearance over the dialysis period

    Time frame: Cohort 5: Day 5

  14. Evaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study Completion

    Incidence, relatedness, and severity of adverse events

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  15. Evaluate Changes in Clinical Laboratory Tests from Baseline Through Study Completion

    Incidence of changes in clinical laboratory measurements from baseline

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  16. Evaluate Change in Vital Signs from Baseline Through Study Completion

    Incidence of changes in blood pressure, pulse, respiratory rate, and temperature

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  17. Evaluate Changes in 12-lead ECG Measurements from Baseline Through Study Completion

    Incidence of changes in 12-lead ECG parameters from baseline

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

  18. Evaluate Physical Examination Abnormalities from Baseline Through Study Completion

    Incidence of physical exam abnormalities

    Time frame: Cohorts 1-4: Day 1 to Day 4; Cohort 5: Day 1 - Day 8

07

Study locations

3 sites
  • Advanced Pharma CR
    Miami, Florida 33147, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jun 2022, 3 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2022
First posted
Mar 17, 2022
StartActual
Feb 21, 2022
Primary completionActual
Jun 10, 2022
CompletionActual
Jun 27, 2022
Last update
Jul 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05283746
Lead sponsor
AN2 Therapeutics, Inc
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Feb 21, 2022
Primary completion
Jun 10, 2022
Completion
Jun 27, 2022
Last update
Jul 15, 2022

Study contacts

Kimberly S Cruz, MD
principal investigator · Advanced Pharma CR LLC
Thomas C Marbury, MD
principal investigator · Orlando Clinical Research Center
George C Canas, MD
principal investigator · Nucleus Network Pty Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion